John MacPhee Net Worth

The estimated Net Worth of John A Mac Phee is at least $1.69 Million dollars as of 12 March 2021. Mr. Phee owns over 192,000 units of Adamas Pharmaceuticals Inc stock worth over $1,619,340 and over the last 10 years he sold ADMS stock worth over $0. In addition, he makes $67,705 as Director at Adamas Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. MacPhee ADMS stock SEC Form 4 insiders trading

John has made over 1 trades of the Adamas Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 192,000 units of ADMS stock worth $128,640 on 12 March 2021.

The largest trade he's ever made was exercising 192,000 units of Adamas Pharmaceuticals Inc stock on 12 March 2021 worth over $128,640. On average, John trades about 19,200 units every 0 days since 2015. As of 12 March 2021 he still owns at least 197,000 units of Adamas Pharmaceuticals Inc stock.

You can see the complete history of Mr. Phee stock trades at the bottom of the page.

John MacPhee biography

John MacPhee serves as Director of the Company. He has served as a member of our Board of Directors since May 2013 and provided consulting services to us from March 2011 to May 2013, and from February 2016 to December 2016. Since 2011, Mr. MacPhee has served as the Executive Director and CEO of The Jed Foundation, a non-profit organization. From 2005 to 2011, Mr. MacPhee served as Executive Vice President of Par Pharmaceutical, Inc. and President of Par’s Strativa Pharmaceuticals division, where he oversaw commercial operations, clinical development, medical affairs, alliance management, and business development. Previously, Mr. MacPhee worked at Forest Laboratories, Inc., where he led the launches of Celexa, Lexapro, and Namenda. Mr. MacPhee also serves as a board member for Blackthorn Therapeutics, a privately-held pharmaceutical company. Mr. MacPhee holds a B.A. from Columbia College, an M.B.A. from New York University, and an M.P.H. from Columbia University.

What is the salary of John MacPhee?

As the Director of Adamas Pharmaceuticals Inc, the total compensation of John MacPhee at Adamas Pharmaceuticals Inc is $67,705. There are 8 executives at Adamas Pharmaceuticals Inc getting paid more, with Neil McFarlane having the highest compensation of $2,080,640.

How old is John MacPhee?

John MacPhee is 45, he's been the Director of Adamas Pharmaceuticals Inc since 2013. There are 11 older and no younger executives at Adamas Pharmaceuticals Inc. The oldest executive at Adamas Pharmaceuticals Inc is Ivan Lieberburg, 70, who is the Independent Director.

What's John MacPhee's mailing address?

John's mailing address filed with the SEC is C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE, CA, 94608.

Insiders trading at Adamas Pharmaceuticals Inc

Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney, and William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.

What does Adamas Pharmaceuticals Inc do?

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Complete history of Mr. Phee stock trades at Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals Inc executives and stock owners

Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Neil McFarlane,
  Chief Executive Officer, Director
• Vijay Shreedhar,
  Chief Commercial Officer
• Christopher Prentiss,
  Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
• David Mahoney,
  Lead Independent Chairman of the Board
• Martha Demski,
  Independent Director
• William Ericson,
  Independent Director
• Michael Bigham,
  Independent Director
• Mardi Dier,
  Independent Director
• Ivan Lieberburg,
  Independent Director
• John MacPhee,
  Director
• Anna Richo,
  Director
• Adrian Quartel,
  Chief Medical Officer
• Adrian Quartel M.D.,
  Chief Medical Officer
• Eric C. Schlezinger,
  Head of HR
• Dr. Jill M. Jene,
  Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management
• Sarah Mathieson,
  Head of Corp. Communications, Patient Advocacy & Engagement
• Richard H Booth,
  Director
• Rajiv Patni,
  Chief Medical Officer
• Ix Lp Seventh Mdv Partners,...,
  
• William J Dawson,
  Chief Financial Officer
• Natalie Mc Clure,
  SVP, Product Development
• Point Partners Llcjay Jeffr...,
  
• Richard King,
  Chief Operating Officer
• Gregory T Went,
  Chief Executive Officer
• Alfred G Merriweather,
  Chief Financial Officer
• Jennifer J Rhodes,
  General Counsel
• Capital Equity Investments,...,
  10% owner
• Sara Grootwassink Lewis,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Grace Shin,
  General Counsel
• Vii Lpmdv Ix Lp Seventh Mdv...,
  
• Ventures Management Iii, Ll...,
  
• Spyros Papapetropoulos,
  Director